Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pamolen
- Development stage
- Preclinical
- Lead developer
- Alessa Therapeutics
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Pamolen is a PARP inhibitor combination therapy being developed by Alessa Therapeutics for the treatment of intermediate to high-risk localized prostate cancer. The therapy utilizes a combination regimen of small molecule PARP inhibitors designed to block PARP-mediated DNA repair through the inhibition of Poly [ADP-ribose] polymerase (PARP). A distinguishing feature of Pamolen is its delivery method, which involves implantable subcutaneous drug delivery devices designed for the extended release of the medication directly to prostate tissue. This localized approach is intended to provide high concentrations of the drug at the tumor site while reducing systemic exposure and associated side effects. As of 2024, the program is in the IND-enabling phase, with an IND filing anticipated in the second half of 2026.
- Brand names
- Pamolen
- Other names
- Pamolen
02
Targets
PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on Pamolen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pamolen.